Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in adults with non-cirrhotic NASH with fibrosis
2022-500594-13-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing AZD4831 with Placebo (2 arms). Primary endpoint: Change from baseline and over placebo to Week 12: ALT. Started Dec 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2022-500594-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500594-13-00.